Monitor upcoming clinical data readouts in Q2 and Q4 2026 as key value drivers, while watching for any updates on the RGX-121 regulatory pathway. The improved cash runway reduces near-term dilution risk.
RGNX drugs
RGNX drug pipeline →- ▲ surabgene lomparvovec 7/10 Phase 3
- ◆ NAVSUNLI 6/10 BLA resubmission pending (accelerated approval) — prior BLA reached PDUFA Feb 8, 2026 and received a Complete Response L
- ◆ RGX-202 6/10 Phase 3 (pivotal topline complete; BLA submission planned)
- ▼ RGX-111 2/10 Phase I/II (on FDA clinical hold since January 2026)
- All RGNX drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $8.72entry
- T+1 · 9mo ago −0.80%α +0.51% · $8.65
- T+5 · 8mo ago +4.13%α +6.37% · $9.08
- T+20 · 8mo ago −2.18%α +1.61% · $8.53
- T+60 · 6mo ago −18.12%α −29.42% · $7.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
REGENXBIO reported financial results for Q4 and full year 2025, showing increased revenue driven by collaboration income and royalty growth, while net loss narrowed year-over-year. The company highlighted clinical progress in its gene therapy pipeline, including upcoming data readouts for RGX-202 in Duchenne muscular dystrophy and sura-vec in wet AMD, but also disclosed ongoing regulatory challenges with RGX-121 following a clinical hold and CRL from the FDA.
Key Financial Metrics
Key Facts
- Revenue increased to $170.4M for FY2025 (from $83.3M in FY2024), driven by $72.9M in upfront license revenue from Nippon Shinyaku partnership and higher Zolgensma/Itvisma royalties
- Net loss narrowed to $193.9M for FY2025 (from $227.1M in FY2024) despite higher R&D and G&A expenses
- Cash position was $240.9M as of December 31, 2025, expected to fund operations into early 2027
- RGX-121 received a Complete Response Letter from FDA and remains on clinical hold, creating regulatory uncertainty
- Multiple near-term catalysts expected in 2026 including topline data for RGX-202 (early Q2) and sura-vec (Q4)
Financial Impact
Revenue nearly doubled year-over-year to $170.4M, while net loss decreased by $33.2M. Cash runway extends into early 2027.
Risk Factors
- Regulatory uncertainty surrounding RGX-121 approval pathway after CRL and clinical hold
- Increasing R&D expenses ($228.3M in 2025) could pressure cash runway if milestones are delayed
- Dependence on partnership revenues and royalty payments creates revenue volatility
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092566 |
| Document: 0001193125-26-092566-index.html | 0001193125-26-092566 |
| Document: 0001193125-26-092566.txt | 0001193125-26-092566 |
Track record
15 reports on RGNX
2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +29.65% at T+60 after the Jul 20, 2026 report. 3 of 6 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.69 Now $7.32 −4.81% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $7.38 Now $7.32 +0.81% settles Feb 3
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $7.71 Now $7.32 −5.06% settles Feb 2
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.93 Now $7.32 +5.70% settles Jan 13
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $7.26 Now $7.32 +0.83% settles Jan 8
- Aug 27, 202611w ago Insider Buy Bullish 5/10 Entry $9.66 Now $7.32 −24.22% settles Nov 23
- Aug 25, 202611w ago 8-K Neutral 3/10 Entry $9.38 Now $7.32 −21.96% settles Nov 19
- Aug 6, 202614w ago 8-K Bullish 7/10 Entry $11.28 to $7.41 Now $7.32 −35.11% ▼ −34.31% −32.88% vs SPY
- Aug 3, 202615w ago Press Release Neutral 1/10 Entry $9.96 to $6.59 Now $7.32 −26.51% ▼ −33.84% −35.62% vs SPY
- Jul 20, 202617w ago 8-K Bearish 6/10 Entry $10.32 to $7.26 Now $7.32 +29.07% ▲ +29.65% +34.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers